Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 Given in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01188252
Recruitment Status : Completed
First Posted : August 25, 2010
Last Update Posted : January 9, 2017
Information provided by (Responsible Party):

Brief Summary:
Clinical study to determine safety, tolerability, to measure how the drug is metabolized by the body and to determine the maximum tolerated dose of BAY1000394 given in an intermittent 3 days on / 4 days off schedule to patients with advanced malignancies

Condition or disease Intervention/treatment Phase
Neoplasms Drug: Roniciclib (BAY1000394) Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 112 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1000394 Given Twice Daily in a 3 Days on / 4 Days Off Schedule in Subjects With Advanced Malignancies
Study Start Date : August 2010
Actual Primary Completion Date : June 2016
Actual Study Completion Date : December 2016

Arm Intervention/treatment
Experimental: Roniciclib Drug: Roniciclib (BAY1000394)
Oral administration twice daily in a 3 days on / 4 days off schedule. Starting dose will be 0.3 mg corresponding to approximately 0.005 mg/kg and dose will be escalated dependent on any dose limiting toxicities.

Primary Outcome Measures :
  1. Safety: Frequency of adverse events [ Time Frame: Up to 3 years or longer if indicated ]
  2. Maximum tolerated dose: Measured by adverse event profile [ Time Frame: Up to 3 years or longer if indicated ]
  3. Pharmacokinetics: Plasma concentrations of BAY1000394 will be measured. The following parameters will be calculated: Cmax, tmax, AUC(0-tn), AUC, and half-life. [ Time Frame: Approximately 6 weeks ]

Secondary Outcome Measures :
  1. Biomarkers evaluation: analysis of apoptosis marker CK18/M30 and total soluble cytokeratin CK18/M65 [ Time Frame: Up to 3 years or longer if indicated ]
  2. Assessment of expression (IHC) and amplification status (FISH) of markers related to cell proliferation and the cell cycle in Paraffin-embedded archival tumor samples. These will include, but may not be limited to Cyclin E, Cyclin D, p21, and Ki67 [ Time Frame: From archival tumor blocks ]
  3. Functional testing of peripheral leucocytes, for example induction of cytokine synthesis [ Time Frame: Approximately 6 weeks ]
  4. Assessment of intracellular biomarkers of apoptosis (for example activated caspase 3, annexin V, expression of MCL 1 for patients with chronic lymphocytic leucemia only [ Time Frame: Approximately 6 weeks ]
  5. Tumor response evaluation based on RECIST 1.1 (solid tumors) or response based on the pertinent guidelines (malignant lymphoma, chronic lymphocytic leukemia) every 2 cycles [ Time Frame: Up to 3 years or longer if indicated ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1
  • Life expectancy of at least 12 weeks
  • Subjects with advanced, histologically or cytologically confirmed solid tumors, refractory to any standard therapy, have no standard therapy available, or subjects must have actively refused any treatment which would be regarded standard, and / or if in the judgment of the investigator, experimental treatment is clinically and ethically acceptable
  • At least 1 tumor lesion measurable by computer tomography (CT) scan or magnetic resonance imaging (MRI) according to RECIST 1.1
  • Adequate bone marrow, liver, and renal functions as assessed by the following laboratory requirements to be conducted within 14 days prior to the first dose of study drug

Exclusion Criteria:

  • History of cardiac disease: congestive heart failure > NYHA Class II, unstable angina (anginal symptoms at rest), any episodes of angina or history of myocardial infarction, cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted), previous venous or arterial thrombotic events, pulmonary embolism
  • Moderate or severe hepatic impairment, i.e. Child-Pugh class B or C(3)
  • History of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
  • Active clinically serious infections of CTCAE > Grade 2 (CTCAE v4.02)
  • Symptomatic metastatic brain or meningeal tumors unless the subject is > 3 months from definitive therapy, has no evidence of tumor growth on an imaging study within 4 weeks prior to study entry, and is clinically stable with respect to the tumor at the time of study entry. Subjects must not be on acute steroid therapy or taper off steroid therapy (chronic steroid therapy is acceptable provided that the dose is stable for 4 weeks prior to study entry and following screening CT / MRI scan). Subjects with neurological symptoms should undergo a CT / MRI scan of the brain to exclude new or progressive brain metastases. Spinal cord metastasis is acceptable
  • Seizure disorder requiring therapy (such as steroids or anti-epileptics)
  • History of organ allograft
  • Evidence or history of bleeding disorder, i.e. any hemorrhage / bleeding event of CTCAE > Grade 2 within 4 weeks prior to prior to the first dose of study drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01188252

Layout table for location information
United States, Missouri
St. Louis, Missouri, United States, 63110
United States, New York
Buffalo, New York, United States, 14263-0001
United States, Ohio
Cleveland, Ohio, United States, 44195
Caen Cedex, France, 14033
Lyon Cedex, France, 69008
Marseille Cedex 20, France, 13915
Villejuif Cedex, France, 94805
Heidelberg, Baden-Württemberg, Germany, 69120
Herne, Nordrhein-Westfalen, Germany, 44625
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT01188252    
Other Study ID Numbers: 14484
2010-019191-79 ( EudraCT Number )
First Posted: August 25, 2010    Key Record Dates
Last Update Posted: January 9, 2017
Last Verified: January 2017
Keywords provided by Bayer:
Phase I
Dose escalation
Kinase inhibitor
Cyclin-dependent kinases
Additional relevant MeSH terms:
Layout table for MeSH terms